The Credit Pharma diclofenac transaction was announced on the same day in September 2017 as the $4.7M capital raising.At the time I thought this deal would materialize.
It was therefore quite a shock to find that this Voveran gel look alike arrangement did not proceed.
I have recently confirmed with POH[not RM]that there were regulatory issues in China surrounding the product that did not suit Credit Pharma and hence no deal was progressed.
I take from this that the ability of POH management to get a deal over the line was never an issue.
Kens
credit pharma miss
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
-0.001(33.3%) |
Mkt cap ! $6.338M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.2¢ | $2.23K | 751.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 63 | 102805577 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 23045578 | 12 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| AVE (ASX) Chart |